Commodore Capital LP — 13F Holdings & Portfolio
CIK 1831942 · latest 13F-HR filed 2026-08-14
Commodore Capital LP manages $1.68B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RLAY (13.37%), ELVN (9.90%), ALKS (9.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 8; 15 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- DEFINIUM THERAPEUTICS INC$56.3M +148.9%
- RELAY THERAPEUTICS INC$55.4M +32.7%
- ENLIVEN THERAPEUTICS INC$37.8M +29.5%
- EYEPOINT INC$29.4M +80.6%
- AMYLYX PHARMACEUTICALS INC$22.9M +29.2%
Top Trims
- NUVALENT INC-$73.1M -85.5%
- CELLDEX THERAPEUTICS INC NEW-$35.3M -41.3%
- TYRA BIOSCIENCES INC-$34.9M -36.8%
- KYMERA THERAPEUTICS INC-$33.8M -54.1%
- SPYRE THERAPEUTICS INC-$21.3M -22.1%
New Positions
- TANGO THERAPEUTICS INC$70.3M
- EDITAS MEDICINE INC$28.8M
- INFLARX NV$16.4M
- RESEARCH ALLIANCE CORP III$5.3M
- VISTAGEN THERAPEUTICS INC$630.2K
Exited Positions
- ERASCA INC$51.4M
- XENON PHARMACEUTICALS INC$48.0M
- NURIX THERAPEUTICS INC$35.3M
- CORVUS PHARMACEUTICALS INC$33.0M
- SOLENO THERAPEUTICS INC$21.8M
Commodore Capital LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $224.5M | 13.37% | 12,000,000 | SH |
| 2 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $166.2M | 9.90% | 3,275,000 | SH |
| 3 | ALKERMES PLC | ALKS | G01767105 | $157.2M | 9.36% | 3,000,000 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $118.0M | 7.03% | 3,050,000 | SH |
| 5 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $101.5M | 6.04% | 5,650,000 | SH |
| 6 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $94.1M | 5.60% | 2,000,000 | SH |
| 7 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $75.2M | 4.48% | 846,786 | SH |
| 8 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $71.9M | 4.28% | 2,723,196 | SH |
| 9 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $70.3M | 4.19% | 2,250,000 | SH |
| 10 | EYEPOINT INC | EYPT | 30233G209 | $65.8M | 3.92% | 4,600,000 | SH |
| 11 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $59.9M | 3.57% | 1,875,000 | SH |
| 12 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $50.4M | 3.00% | 1,939,000 | SH |
| 13 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $50.2M | 2.99% | 1,350,000 | SH |
| 14 | PHARVARIS N V | PHVS | N69605108 | $49.3M | 2.93% | 1,425,000 | SH |
| 15 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $48.7M | 2.90% | 1,500,000 | SH |
| 16 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $38.9M | 2.32% | 1,415,000 | SH |
| 17 | EDITAS MEDICINE INC | EDIT | 28106W103 | $28.8M | 1.72% | 8,889,000 | SH |
| 18 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $28.7M | 1.71% | 250,000 | SH |
| 19 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $21.6M | 1.29% | 6,336,782 | SH |
| 20 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $21.3M | 1.27% | 8,695,652 | SH |
| 21 | ZURA BIO LTD | ZURA | G9TY5A101 | $19.2M | 1.14% | 3,250,000 | SH |
| 22 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $18.8M | 1.12% | 1,018,319 | SH |
| 23 | INFLARX NV | IFRX | N44821101 | $16.4M | 0.97% | 7,300,000 | SH |
| 24 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $14.2M | 0.85% | 2,933,680 | SH |
| 25 | NUVALENT INC | NUVL | 670703107 | $12.3M | 0.74% | 100,000 | SH |
| 26 | SAB BIOTHERAPEUTICS INC | SABS | 78397T202 | $11.2M | 0.67% | 2,870,000 | SH |
| 27 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $11.0M | 0.65% | 5,397,488 | SH |
| 28 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $9.9M | 0.59% | 1,425,000 | SH |
| 29 | PEPGEN INC | PEPG | 713317105 | $8.1M | 0.48% | 4,475,000 | SH |
| 30 | RESEARCH ALLIANCE CORP III | RACC | G75226103 | $5.3M | 0.32% | 500,000 | SH |
| 31 | HELIX ACQUISITION CORP III | HLXC | G4444S107 | $5.3M | 0.32% | 500,000 | SH |
| 32 | LEONABIO INC | LONA | 04746L203 | $4.3M | 0.25% | 464,398 | SH |
| 33 | VISTAGEN THERAPEUTICS INC | VTGN | 92840H400 | $630.2K | 0.04% | 2,788,620 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.68B | 33 | 0001831942-26-000033 |
| 2026-03-31 | 2026-05-15 | $1.73B | 36 | 0001831942-26-000025 |
| 2025-12-31 | 2026-02-17 | $1.50B | 33 | 0001831942-26-000004 |
| 2025-09-30 | 2025-11-14 | $2.05B | 37 | 0001831942-25-000023 |
35TH FLOOR
NEW YORK, NY 10022